Tuesday, March 12, 2013

Thoughts, Formulas And Techniques For the cdk1 inhibitor Cell Cycle inhibitor

Danshensu was obtained from Shandong Luye Pharmaceutical Co., Ltd.. Verapamil was obtained from Shanghai Hefeng Pharmaceutical Co., cdk1 inhibitor Ltd.. Naproxen was obtained from National Institute for your Manage of Pharmaceutical and Biological Items.

The rats were kept with cost-free accessibility to food and water on a 12 h light/dark cdk1 inhibitor cycle. They were housed in plastic cages and randomly divided into two groups with 24 animals in each group: the control group and the verapamil group. The rats in the verapamil group were administered intraperitoneally with verapamil at a dose of 20 mg kg1. The rats in the control group were treated with the same volume of normal saline. Ninety minutes later, all rats were treated intravenously with Danshensu by tail vein. At 15 min, 30 min, and 60 min after Danshensu treatment, the animals were anesthetized with chloral hydrate and then 5 mL heparinized blood were collected from abdominal aorta and the rats were perfused with 100 mL of ice cold normal saline each.

The mobile phase was acetonitrilewater. The pump was operated NSCLC at a ow rate of 0. 2 mL min1. Separations were performed at the temperature of 20 C. Mass spectrometric detection was performed using a TSQ Quantum tandem mass spectrometer equipped with an electrospray ionization source. Quantication was performed using selected reaction monitoring of the transitions of m/z 197. 0 m/z 135. 1 for Danshensu and m/z 229. 0 m/z 170. 1 for the naproxen. The mass spectrum conditions were optimized as follows: spray voltage, 3000 V, sheath gas pressure, 30 psi, auxiliary gas pressure, 5 arbitrary unit, capillary temperature, 350 C, collision induced dissociation voltage, 18 V, argon gas pressure, 1. 5 millitorr. Data acquisition was performed with Xcalibur software.

The retention times of Danshensu and naproxen were 1. 8 and 4. cdk1 inhibitor 2 min in brain and 1. 7 and 4. 3 min in plasma, respectively.

No comments:

Post a Comment